Summary:
- This article discusses the latest advancements in the development of CRISPR-based gene-editing therapies, specifically focusing on their clinical application for treating hereditary blood disorders.
- It highlights the challenges of off-target effects and the ongoing regulatory efforts to ensure patient safety while accelerating the transition of these genomic tools from laboratory research to medical practice.